Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2019-04-18 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia phase I clinical results on the antibody CAN04 selected for oral presentation at ASCO
Regulatory Filings Classification · 99% confidence The document is a 'Press release' dated April 18, 2019, announcing that clinical data for the antibody CAN04 will be presented orally at the ASCO meeting. It details the presentation time, location, and the abstract's future public release date. Crucially, the final paragraph states: 'This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation.' This structure—a brief announcement of an event or information release, often mandated by regulation, and not being a full financial report (like 10-K or IR) or a transcript—points towards a general regulatory disclosure. Since it is not a specific filing type like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), and it is an announcement of an external event (conference presentation), the most appropriate general category for a mandatory, non-specific regulatory disclosure that doesn't fit elsewhere is 'Regulatory Filings' (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just announces the publication of *another* report.
2019-04-18 English
Cantargias fas I kliniska resultat för antikroppen CAN04 utvalda för muntlig presentation på ASCO
Regulatory Filings Classification · 99% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated April 18, 2019. It announces that Phase I clinical trial data for their antibody CAN04 has been selected for an oral presentation at the 2019 Annual ASCO meeting. This is an announcement about the presentation of clinical results, not the full clinical report itself, nor is it a standard regulatory filing like a 10-K or an earnings release. Since it is an announcement regarding clinical trial data presentation at a major conference, it most closely aligns with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the context of clinical trial updates being presented to investors/the public, and the document being a formal announcement of this event, it fits best under Investor Presentation (IP) as it details upcoming data presentation, or RNS as a general regulatory announcement. However, since it is specifically about presenting clinical results at a major medical conference, which is key information for investors, IP is a strong candidate. If the document were the actual abstract or presentation slides, IP would be certain. As it is an announcement *about* the presentation, and it doesn't fit other specific categories like ER, AR, or LTR (legal), RNS is the safest general regulatory fallback, but IP captures the intent better. Given the options, and that it's a specific announcement about data dissemination, I will lean towards RNS as the most appropriate general regulatory announcement category for non-standard filings, as it is not a formal financial report or a standard investor presentation deck.
2019-04-18 Swedish
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly details a change in shareholding for a specific holder ('Alecta pensionsförsäkring, ömsesidigt') concerning the issuer 'CANTARGIA AB'. It includes fields like 'Before the transaction', 'After the transaction', 'Quantity', 'Percentage', and specifically states the 'Reason for major shareholding notification' as 'New share issue'. This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized as 'MRQ' in the provided schema.
2019-04-05 English
Cantargia makes a directed share issue of approximately SEK 106 million for increased investments in the clinical development of CAN04
Capital/Financing Update Classification · 99% confidence The document is a press release announcing that the board of directors has resolved on a 'directed share issue of approximately SEK 106 million'. This action involves issuing new shares and raising capital, which directly relates to the company's financing activities and capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific corporate finance event.
2019-03-21 English
Cantargia genomför riktad nyemission om cirka 106 miljoner kronor för utökad klinisk satsning på CAN04
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that the Board of Directors has decided to conduct a 'riktad nyemission' (directed new share issue) to raise approximately 106 million SEK. This action involves issuing new shares to specific institutional and private investors to fund expanded clinical trials for their drug candidate CAN04. This activity directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (4912 chars) is substantial enough that it is the primary announcement, not just a notice of publication (RPA).
2019-03-21 Swedish
Earnings Release 2018
Earnings Release Classification · 99% confidence The document is titled "BOKSLUTSKOMMUNIKÉ" (Year-End Report Communication) and provides detailed financial figures for the period January - December 2018, including quarterly results (Q4) and full-year results. It contains key financial metrics like Net Sales, Operating Result, Net Result after tax, Earnings per share, Equity ratio (Soliditet), and Cash/Short-term investments. It also includes a CEO commentary and detailed sections on R&D costs, financial position, and market analysis related to their drug development pipeline (CAN04). This structure—comprehensive financial review for the full fiscal year, including comparative figures and management discussion—is characteristic of an Annual Report or a comprehensive year-end financial statement release. Since the text is extensive (over 45,000 characters) and contains the full financial details, it is classified as the primary annual report document, which corresponds to the '10-K' definition in the US context, or the comprehensive annual financial report in general. Given the options, '10-K' is the closest fit for a full annual financial report, although the document is Swedish. If a specific 'Annual Financial Report' code existed, it would be preferred, but 10-K serves as the proxy for the comprehensive annual filing. Q4 2018
2019-02-27 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.